Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate + reboxetine
- Development stage
- Unknown
- Lead developer
- University of Haifa
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Methylphenidate + reboxetine is a combination therapy being investigated by the University of Haifa for the treatment of post-traumatic stress disorder (PTSD). This pharmacological approach combines methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine, with reboxetine, a selective norepinephrine reuptake inhibitor (SNRI). The treatment rationale is based on the hypothesis that impaired attentional and sensory processing, mediated by dopaminergic and noradrenergic pathways, contributes significantly to PTSD symptoms such as re-experiencing, avoidance, and hyperarousal. By dual-targeting these neurotransmitter systems, the therapy aims to improve cognitive control and emotional regulation. It is currently being evaluated in a Phase 2 clinical trial (NCT05133804) involving adults with PTSD.
- Other names
- Methylphenidate and ReboxetineReboxetine and Methylphenidate
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on methylphenidate + reboxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate + reboxetine.